Wanjia Group (00401.HK) 2025 Market Performance and Risk Analysis

Wanjia Group (00401.HK) is a medical distribution industry enterprise mainly engaged in pharmaceutical wholesale and hemodialysis services [0]. Its share price has risen significantly (+182%) year-to-date in 2025, but its interim financial performance is poor, with a loss attributable to shareholders of HK$712,000 (compared to a profit of HK$1.256 million in the same period last year) [0]. The market capitalization is approximately HK$78.43 million, and the 52-week high and low prices are HK$0.182 and HK$0.044 respectively [0].

Despite the considerable share price increase, the stock’s fundamentals have not improved, and liquidity is extremely poor—on some trading days, both trading volume and turnover are HK$0 [0]. A technical chart pattern “Range Breakout” appeared on November 21, but there was no change in share price and no trading volume that day, reflecting a quiet market [0].

: 1) Interim results are in loss, fundamentals are deteriorating; 2) Sluggish trading volume, high liquidity risk; 3) Extremely low market attention, lack of institutional coverage [0]. : If the company achieves a fundamental turnaround, there may be room for valuation repair, but there are no obvious signals currently [0].

Wanjia Group (00401.HK)'s share price performance deviates from its fundamentals; the high increase is not accompanied by profit improvement, and liquidity is insufficient. Investors should treat it cautiously and pay attention to subsequent financial data and changes in trading volume [0].